Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Severe COVID-19 Pneumonia
NCT04320615Phase 3Completed
- Sponsor
- Roche
- Start
- Apr 2020
- Primary completion
- Jun 2020
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in COVID-19 pneumonia comparing Tocilizumab (TCZ) Arm with Placebo Arm (2 arms). Primary endpoint: Clinical Status Assessed Using a 7-Category Ordinal Scale at Day 28. Started Apr 2020; status: completed.
02
Drugs
tocilizumab
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04320615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04320615.